Marinus Pharmaceuticals (MRNS)
(Real Time Quote from BATS)
$1.35 USD
+0.02 (1.50%)
Updated May 20, 2024 03:34 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
Marinus Pharmaceuticals, Inc. [MRNS]
Reports for Purchase
Showing records 41 - 56 ( 56 total )
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Refractory Status Epilepticus Phase 3 Gains Greenlight From FDA to Begin Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways From Our Coverage at the 2020 H.C. Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ganaxolone Blooms in MARIGOLD Phase 3 For Treatment of CDD Epilepsy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Marinus Shows Why People Are Starting to Pay Attention; PT to $9, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
HCW @ Home With Marinus Take-Aways and R-D Day Preview; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Don''t Sleep on New Mechanisms for MDD: A Look at GABA Modulation and Orexin-2 Antagonists
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Ganaxolone Stays on Track; Reiterate Buy With PT of $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
With Balance Sheet Bolstered, Marinus Is Ready for a "Breakthrough"; Raise Target to $6, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Perspectives from KOL Dinner on Major Depressive Disorder
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pivotal Readouts Galore Over the Next 24 Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Marinus Pharmaceuticals, Inc.
Industry: Medical - Drugs
PK Data Offers Additional Validation for Ganaxolone''s Effect in RSE
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D